Sorrento Therapeutics Inc (SRNE) Expected to Announce Earnings of -$0.35 Per Share

Analysts expect that Sorrento Therapeutics Inc (NASDAQ:SRNE) will post earnings per share of ($0.35) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Sorrento Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.32) and the lowest estimate coming in at ($0.39). Sorrento Therapeutics reported earnings of ($0.38) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 7.9%. The firm is scheduled to issue its next earnings results on Thursday, May 9th.

According to Zacks, analysts expect that Sorrento Therapeutics will report full year earnings of ($1.31) per share for the current year, with EPS estimates ranging from ($1.43) to ($1.17). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.80) per share, with EPS estimates ranging from ($0.88) to ($0.71). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Sorrento Therapeutics.

A number of research analysts have issued reports on SRNE shares. HC Wainwright set a $40.00 price objective on Sorrento Therapeutics and gave the company a “buy” rating in a research note on Wednesday, January 23rd. BidaskClub lowered Sorrento Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, January 22nd. ValuEngine lowered Sorrento Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. B. Riley boosted their price target on Sorrento Therapeutics from $10.50 to $12.00 and gave the company a “buy” rating in a report on Wednesday, March 20th. Finally, Zacks Investment Research lowered Sorrento Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, February 2nd. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $20.67.

Institutional investors have recently made changes to their positions in the company. InterOcean Capital LLC purchased a new position in shares of Sorrento Therapeutics in the fourth quarter valued at about $25,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of Sorrento Therapeutics in the first quarter valued at about $30,000. Paloma Partners Management Co purchased a new position in shares of Sorrento Therapeutics in the fourth quarter valued at about $34,000. Amalgamated Bank purchased a new position in shares of Sorrento Therapeutics in the fourth quarter valued at about $35,000. Finally, Metropolitan Life Insurance Co. NY lifted its position in shares of Sorrento Therapeutics by 356.6% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 30,211 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 23,595 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

SRNE traded down $0.10 on Friday, hitting $3.96. 10,250 shares of the company were exchanged, compared to its average volume of 5,629,129. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.91 and a quick ratio of 2.91. Sorrento Therapeutics has a 12 month low of $1.80 and a 12 month high of $8.25. The firm has a market cap of $496.46 million, a price-to-earnings ratio of 30.75 and a beta of 2.64.

Sorrento Therapeutics Company Profile

Sorrento Therapeutics, Inc, a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. It offers resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for the treatment of intractable pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia.

Featured Article: What are the FAANG Stocks?

Get a free copy of the Zacks research report on Sorrento Therapeutics (SRNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sorrento Therapeutics (NASDAQ:SRNE)

Receive News & Ratings for Sorrento Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sorrento Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.